Guardant Health, Inc.GHNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology.

fool.com

Should You Buy Guardant Health Before Feb. 19?

Guardant Health hasn't scheduled its Q4 update yet but will likely report results by Feb. 19, 2026. The precision oncology company has had a lot of good news recently.

businesswire.com

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.

seekingalpha.com

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.

defenseworld.net

Guardant Health, Inc. $GH Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 21.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,776,369 shares of the company's stock after purchasing an additional 310,931 shares during the quarter. Federated

defenseworld.net

Alta Wealth Advisors LLC Purchases Shares of 6,496 Guardant Health, Inc. $GH

Alta Wealth Advisors LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ: GH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,496 shares of the company's stock, valued at approximately $406,000. A number of other hedge

seekingalpha.com

Guardant Health: Look For Explosive Revenue Growth Ahead

Guardant Health, Inc. is rated a Buy, driven by explosive growth potential in cancer and multi-disease screening, notably via its Shield blood test. GH's Shield is the first FDA-approved blood test for primary colorectal cancer screening, with rapid early adoption and significant pricing power due to ADLT status. GH's integrated platform, product breadth, and first-mover advantage in blood-based CRC screening position it to take share from Natera and expand into new markets.

seekingalpha.com

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Nebius Group, Wix.com Ltd., and Rezolute, Inc. were among the top detractors from performance.

defenseworld.net

Gamehost (TSE:GH) Share Price Passes Below 200 Day Moving Average – Here’s Why

Shares of Gamehost Inc. (TSE: GH - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of C$11.83 and traded as low as C$11.79. Gamehost shares last traded at C$11.79, with a volume of 101 shares changing hands. Gamehost Trading Down 0.3% The company

seekingalpha.com

Artisan Small Cap Fund Q4 2025 Portfolio Activity

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

benzinga.com

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

On Thursday, the U.S. Food and Drug Administration (FDA) approved Guardant Health Inc.'s (NASDAQ: GH) Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with Braftovi (encorafenib) in combination with cetuximab and chemotherapy.

businesswire.com

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling. The accelerated approval was su.

seekingalpha.com

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractors from performance. During the quarter, Robinhood shares detracted from performance, primarily due to a sharp decline in cryptocurrency markets.

defenseworld.net

Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC

Emerald Advisers LLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 24.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 873,203 shares of the company's stock after purchasing an additional 173,281 shares during the quarter.

businesswire.com

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck's oncology portfolio using the Guardant Infinity™ Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: Use Guardant's portfolio of liquid and tissue biopsy tests as clinical trial enrolling.

seekingalpha.com

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH's Shield test addresses major barriers to screening, expanding access to 50 million Americans and driving a 335% YoY increase in screening volumes. Revenue growth remains robust, with FY2025 revenue at $981 million (+33% YoY) and Q4 preliminary revenue of $280 million (+39% YoY), outpacing peers.

seekingalpha.com

Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

defenseworld.net

Guardant Health, Inc. $GH Shares Sold by D.A. Davidson & CO.

D.A. Davidson and CO. lessened its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 59.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,847 shares of the company's stock after selling 23,466 shares during the

businesswire.com

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximately $280 million, an increase of 39% Reported approximately 79,000 oncology tests, an increase of 38% Report.

defenseworld.net

Terilyn Monroe Sells 10,031 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ: GH - Get Free Report) insider Terilyn Monroe sold 10,031 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total transaction of $1,124,274.48. Following the transaction, the insider directly owned 20,990 shares of the company's stock, valued

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance